Literature DB >> 2196355

Prenatal and postnatal corticosteroid therapy to prevent neonatal necrotizing enterocolitis: a controlled trial.

E Halac1, J Halac, E F Bégué, J M Casañas, D R Indiveri, J F Petit, M J Figueroa, J M Olmas, L A Rodríguez, R J Obregón.   

Abstract

To determine whether prenatal corticosteroid therapy would reduce the incidence of neonatal necrotizing enterocolitis (NEC), we assigned a total of 466 women admitted in premature labor either to receive placebo (group A, n = 256), if delivery was expected to occur within 24 hours of admission, or to receive betamethasone (group B, n = 210) if delivery was expected to take place more than 24 hours after admission. All women were free of severe medical complications or drug therapy; cases of intrauterine growth retardation or premature rupture of the membranes were excluded. Their newborn infants, excluding malformed, congenitally infected, and growth-retarded infants, were enrolled in the study unless they had died before the age of 10 postnatal days. Babies born to group A mothers (n = 248) were further assigned to a treatment group (group A1, n = 130) receiving dexamethasone, 2 mg/kg/day by intravenous injection during the first 7 days of life, or to a control group (group A2, n = 118) receiving 10% dextrose solution placebo. Group B infants (prenatal betamethasone, n = 205) received neither treatment nor placebo. The incidence of NEC in group A1 was 6.9% (9/130), and in group A2 it was 14.4% (17/118) (p less than 0.05). In group B the incidence was 3.4% (7/205); this was much lower than in group A2 (p less than 0.01) and lower than in group A combined (10.4%) (p less than 0.01). There was no death from NEC and no surgical intervention among group B patients. The mortality rate for group A1 (11%) was lower than for group A2 (56%) (p less than 0.02). There were fewer indications for surgical intervention for NEC in group A1 than in group A2. Histologic studies confirmed bowel ischemia in all specimens analyzed. These data support the hypothesis that the incidence of NEC is significantly reduced after prenatal steroid treatment. Although postnatal therapy with steroids does not decrease the incidence as effectively as prenatal therapy, it improves clinical outcome of NEC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2196355     DOI: 10.1016/s0022-3476(05)72461-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  31 in total

1.  Hydrocortisone-induced anti-inflammatory effects in immature human enterocytes depend on the timing of exposure.

Authors:  Samuli Rautava; W Allan Walker; Lei Lu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-04-07       Impact factor: 4.052

2.  Effects of dexamethasone on small bowel and kidney oxidative stress and histological alterations in bile duct-ligated rats.

Authors:  Hayrettin Ozturk; Halil Eken; Hulya Ozturk; Huseyin Buyukbayram
Journal:  Pediatr Surg Int       Date:  2006-08-01       Impact factor: 1.827

Review 3.  Impact of standardised feeding regimens on incidence of neonatal necrotising enterocolitis: a systematic review and meta-analysis of observational studies.

Authors:  S K Patole; N de Klerk
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-03       Impact factor: 5.747

Review 4.  Necrotizing enterocolitis: a practical guide to its prevention and management.

Authors:  Pinaki Panigrahi
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 5.  New concepts of microbial translocation in the neonatal intestine: mechanisms and prevention.

Authors:  Michael P Sherman
Journal:  Clin Perinatol       Date:  2010-09       Impact factor: 3.430

6.  Early neonatal dexamethasone treatment for prevention of bronchopulmonary dysplasia. Randomised trial and meta-analysis evaluating the duration of dexamethasone therapy.

Authors:  Eija Anttila; Outi Peltoniemi; Dominique Haumont; Egbert Herting; Henk ter Horst; Kirsti Heinonen; Pentti Kero; Päivi Nykänen; Sidarto Bambang Oetomo; Mikko Hallman
Journal:  Eur J Pediatr       Date:  2005-04-28       Impact factor: 3.183

7.  Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin.

Authors:  J L Grosfeld; M Chaet; F Molinari; W Engle; S A Engum; K W West; F J Rescorla; L R Scherer
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

8.  Enteral glutamine supplementation and dexamethasone attenuate the local intestinal damage in rats with experimental necrotizing enterocolitis.

Authors:  Alaeddin Dilsiz; Ilhan Ciftçi; T Murad Aktan; Mehmet Gürbilek; Emrah Karagözoğlu
Journal:  Pediatr Surg Int       Date:  2003-10-11       Impact factor: 1.827

9.  Absence of lysozyme (muramidase) in the intestinal Paneth cells of newborn infants with necrotising enterocolitis.

Authors:  H B Coutinho; H C da Mota; V B Coutinho; T I Robalinho; A F Furtado; E Walker; G King; Y R Mahida; H F Sewell; D Wakelin
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

Review 10.  Necrotizing enterocolitis: a multifactorial disease with no cure.

Authors:  Kareena-L Schnabl; John-E Van Aerde; Alan-Br Thomson; Michael-T Clandinin
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.